Published in J Virol on January 01, 2010
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother (2010) 2.50
Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol (2010) 2.17
Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology (2014) 1.85
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother (2010) 1.84
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J Virol (2011) 1.47
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol (2011) 1.44
Inhibition of dengue virus by targeting viral NS4B protein. J Virol (2011) 1.31
Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity. PLoS Pathog (2012) 1.23
Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother (2012) 1.21
Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob Agents Chemother (2010) 1.17
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother (2012) 1.17
Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins. J Virol (2010) 1.15
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother (2013) 1.11
The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology (2011) 1.10
Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep (2014) 1.10
Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother (2012) 1.09
Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J Biol Chem (2010) 1.07
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother (2012) 1.06
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother (2011) 1.05
Correlation between NS5A dimerization and hepatitis C virus replication. J Biol Chem (2012) 1.01
A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity. PLoS Pathog (2014) 0.99
Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther (2013) 0.98
Diacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core. J Biol Chem (2013) 0.97
Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase. Antimicrob Agents Chemother (2014) 0.95
Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother (2011) 0.95
The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci (2014) 0.93
Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother (2014) 0.93
Synthesis and evaluation of novel potent HCV NS5A inhibitors. Bioorg Med Chem Lett (2012) 0.92
Hepatitis C: An unsuspected drug target. Nature (2010) 0.89
Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses (2010) 0.87
Intrinsically unstructured domain 3 of hepatitis C Virus NS5A forms a "fuzzy complex" with VAPB-MSP domain which carries ALS-causing mutations. PLoS One (2012) 0.87
Hepatitis C virus experimental model systems and antiviral drug research. Virol Sin (2010) 0.87
Daclatasvir: potential role in hepatitis C. Drug Des Devel Ther (2013) 0.84
Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures. Antimicrob Agents Chemother (2011) 0.84
TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future (2011) 0.83
Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses (2010) 0.83
Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding. Viruses (2014) 0.82
NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes. Antimicrob Agents Chemother (2014) 0.82
Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol (2016) 0.81
Direct binding of a hepatitis C virus inhibitor to the viral capsid protein. PLoS One (2012) 0.81
Expanding the proteome of an RNA virus by phosphorylation of an intrinsically disordered viral protein. J Biol Chem (2014) 0.80
Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor. Antimicrob Agents Chemother (2011) 0.80
Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems. Antimicrob Agents Chemother (2012) 0.79
A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants. PLoS One (2014) 0.78
Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides. Virology (2014) 0.78
Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro. Antiviral Res (2014) 0.76
Update on the Development of Anti-Viral Agents Against Hepatitis C. J Clin Transl Hepatol (2013) 0.75
Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors. ACS Med Chem Lett (2013) 0.75
Antiviral drugs: New oral HCV drug shows promise. Nat Rev Drug Discov (2010) 0.75
Application of next generation sequencing for the detection of human viral pathogens in clinical specimens. J Clin Virol (2016) 0.75
Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. Antiviral Res (2015) 0.75
Amino Acid Mutations in the NS4A Region of Hepatitis C Virus Contribute to Viral Replication and Infectious Virus Production. J Virol (2016) 0.75
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 24.31
Efficient initiation of HCV RNA replication in cell culture. Science (2000) 15.12
The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol (2007) 8.98
Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol (1993) 8.47
Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol (2001) 6.71
Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol (2002) 6.69
Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol (2001) 6.37
Effect of alpha interferon on the hepatitis C virus replicon. J Virol (2001) 6.18
Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A (1997) 6.09
Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J (1996) 5.47
A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A (1993) 4.30
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature (2005) 3.83
Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog (2008) 3.77
Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol (1994) 3.51
Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol (1995) 3.41
The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem (2004) 3.15
Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol (2004) 2.97
Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Commun (1994) 2.89
Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. J Biol Chem (2005) 2.61
Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol (2009) 2.39
The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J Virol (1996) 2.30
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A (2002) 2.11
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob Agents Chemother (2005) 1.94
Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. J Virol (1999) 1.75
Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J Virol (2004) 1.71
A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2008) 1.48
Efficient rescue of hepatitis C virus RNA replication by trans-complementation with nonstructural protein 5A. J Virol (2005) 1.47
The alpha isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylation. J Virol (2006) 1.19
Hepatitis C virus therapy to date. Antivir Ther (2008) 1.16
Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase. Expert Opin Drug Discov (2009) 1.16
Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew Chem Int Ed Engl (2003) 1.13
Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology (2005) 1.10
Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. Bioorg Med Chem Lett (2009) 0.94
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements. EMBO J (2002) 4.13
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet (2009) 3.59
A role for small RNAs in DNA double-strand break repair. Cell (2012) 3.15
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A (2003) 2.92
Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. J Invest Dermatol (2007) 2.59
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother (2010) 2.50
Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci U S A (2006) 2.49
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology (2012) 2.29
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22
True versus reported waiting times for valvular aortic stenosis surgery. Can J Cardiol (2006) 2.21
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Significant improvement in short-term mortality in women undergoing coronary artery bypass surgery (1991 to 2004). J Am Coll Cardiol (2007) 2.11
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology (2011) 2.10
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob Agents Chemother (2005) 1.94
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother (2012) 1.85
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology (2011) 1.83
A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. EMBO J (2003) 1.72
Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol (2003) 1.70
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem (2003) 1.57
Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor. Bioorg Med Chem Lett (2003) 1.53
Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol (2006) 1.52
Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol (2002) 1.47
Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. Nat Genet (2011) 1.46
Small intestinal hemolymphangioma with bleeding: a case report. World J Gastroenterol (2012) 1.45
Identifying priorities in methodological research using ICD-9-CM and ICD-10 administrative data: report from an international consortium. BMC Health Serv Res (2006) 1.45
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol (2011) 1.44
Angina with "normal" coronary arteries: sex differences in outcomes. Am Heart J (2007) 1.41
The mortality rate from anorexia nervosa. Int J Eat Disord (2005) 1.40
Trends in wait times for cardiac revascularization. Can J Cardiol (2011) 1.39
Percutaneous coronary intervention and 30-day mortality: the British Columbia PCI risk score. Catheter Cardiovasc Interv (2009) 1.37
Acanthamoeba keratitis: clinical characteristics and management. Ophthalmology (2006) 1.36
Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc Natl Acad Sci U S A (2004) 1.30
Specific inhibition of bovine viral diarrhea virus replicase. J Virol (2003) 1.28
Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population. PLoS Genet (2008) 1.26
Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother (2004) 1.26
Confirmation by exome sequencing of the pathogenic role of NCSTN mutations in acne inversa (hidradenitis suppurativa). J Invest Dermatol (2011) 1.23
Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia (2012) 1.22
Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation. J Clin Invest (2006) 1.21
Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene (2005) 1.19
Outcome of mitral valve repair or replacement: a comparison by propensity score analysis. Circulation (2003) 1.19
Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci U S A (2011) 1.17
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother (2012) 1.17
A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog (2010) 1.16
Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol (2006) 1.12
Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet (2012) 1.12
Human RIF1 encodes an anti-apoptotic factor required for DNA repair. Carcinogenesis (2009) 1.12
Evolution and expression analysis of the grape (Vitis vinifera L.) WRKY gene family. J Exp Bot (2014) 1.11
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother (2013) 1.11
Do younger women fare worse? Sex differences in acute myocardial infarction hospitalization and early mortality rates over ten years. J Womens Health (Larchmt) (2013) 1.11
Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology (2005) 1.10
Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother (2012) 1.09
The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol (2011) 1.08
Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet (2009) 1.07
Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res (2012) 1.07
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother (2012) 1.06
In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother (2012) 1.05
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother (2011) 1.05
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. Arthritis Rheum (2010) 1.03
Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. Am Heart J (2013) 1.02
Multi-detector CT enterography with iso-osmotic mannitol as oral contrast for detecting small bowel disease. World J Gastroenterol (2005) 1.01
A novel linkage to generalized vitiligo on 4q13-q21 identified in a genomewide linkage analysis of Chinese families. Am J Hum Genet (2005) 1.00
Genomic organization, phylogenetic comparison and differential expression of the SBP-box family genes in grape. PLoS One (2013) 1.00
Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother (2004) 1.00
Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins (2014) 0.99
Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population. J Invest Dermatol (2012) 0.98
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut (2013) 0.98
Defining NOTCH3 target genes in ovarian cancer. Cancer Res (2012) 0.97
Revascularization use and survival outcomes after cardiac catheterization in British Columbia and Alberta. Can J Cardiol (2004) 0.97
Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol (2007) 0.96
Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethyl-5-hydroxy-cyclohexylmethylamine. Bioorg Med Chem Lett (2002) 0.96
Sex differences in mortality after transcatheter aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol (2012) 0.96
Genome-wide identification and analysis of the TIFY gene family in grape. PLoS One (2012) 0.95
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem (2014) 0.95
Characterizations of HCV NS5A replication complex inhibitors. Virology (2013) 0.95
Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Digestion (2009) 0.94
Growth and performance of yttrium oxide as an ideal high-kappa gate dielectric for carbon-based electronics. Nano Lett (2010) 0.94